Literature DB >> 7581111

Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation.

W A Marijt1, N A Kernan, T Diaz-Barrientos, W F Veenhof, R J O'Reilly, R Willemze, J H Falkenburg.   

Abstract

Graft rejection after T cell-depleted HLA-genotypically identical bone marrow transplantation (BMT) is probably mediated by mH antigen-specific cytotoxic T lymphocytes (CTL). We have analyzed peripheral blood mononuclear cells (PBMC) from a female bone marrow graft recipient, collected during graft rejection after a sex mismatched HLA-identical BMT. A CTL line was generated by stimulating recipient PBMC collected during graft rejection with donor PBMC and donor EBV-transformed lymphoblastoid cell lines. From this CTL line a large number of clones of different specificity and phenotype was established by limiting dilution. These clones exhibited several mH antigen specificities, restricted by HLA-B7, -B27 or -DR2 as shown by differential recognition of family members and unrelated individuals sharing potential restriction elements. The CD3+CD4+ and CD3+CD8+ bulk culture was cloned, resulting in 50 HLA-B7 restricted CD3+CD4-CD8+CTL clones, three HLA-B27 restricted CD3+CD4-CD8+CTL clones, one HLA-DR2 restricted CD3+CD4+CD8-CTL clone and two additional HLA class II restricted CD3+CD4+CD8-CTL clones with a different specificity. One representative clone of each specificity was selected for further analysis. The CTL line and the HLA-B7 restricted CD8+CTL clone, but not the HLA class II restricted CD4+ CTL clone, inhibited the growth of donor hematopoietic progenitor cells (HPC). In conclusion, these results show that graft rejection after HLA-identical BMT may be mediated by multiple CTL clones that specifically recognize one mH antigen peptide presented by different HLA molecules or different mH antigens expressed on donor cells and that CTL, but not CD4+ CTL inhibited donor HPC growth.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7581111

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies.

Authors:  Marleen M van Loenen; Renate de Boer; Renate S Hagedoorn; Esther H M van Egmond; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

2.  Survival and function of MiHA epitope-specific host CD8 TM cells following ablative conditioning and HCT.

Authors:  Alwi M Shatry; Derry C Roopenian; Robert B Levy
Journal:  Biol Blood Marrow Transplant       Date:  2007-03       Impact factor: 5.742

3.  Minor antigens on transfused RBCs crossprime CD8 T cells but do not induce full effector function.

Authors:  M Desmarets; G Mylvaganam; E K Waller; C D Josephson; C Pack; A E Lukacher; J C Zimring
Journal:  Am J Transplant       Date:  2011-09       Impact factor: 8.086

Review 4.  T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.

Authors:  R J O'Reilly; G Koehne; A N Hasan; E Doubrovina; S Prockop
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

5.  A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells.

Authors:  Marleen M van Loenen; Renate de Boer; Ellis van Liempt; Pauline Meij; Inge Jedema; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2013-12-13       Impact factor: 9.941

6.  Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.

Authors:  W A Erik Marijt; Mirjam H M Heemskerk; Freke M Kloosterboer; Els Goulmy; Michel G D Kester; Menno A W G van der Hoorn; Simone A P van Luxemburg-Heys; Manja Hoogeboom; Tuna Mutis; Jan Wouter Drijfhout; Jon J van Rood; Roel Willemze; J H Frederik Falkenburg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-24       Impact factor: 11.205

7.  Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma.

Authors:  P A Holloway; N Kaldenhoven; H M Kok-Schoemaker; B Van Kessel; W T M Van Blokland; A C Bloem; H M Lokhorst
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.